NCT01989780View on ClinicalTrials.gov

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2019

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Paclitaxel

DRUG

Bevacizumab

DRUG

Letrozole

DRUG

Anastrozole

DRUG

Exemestane

DRUG

Fulvestrant

DRUG

Goserelin

DRUG

leuprorelin

Trial Locations (1)

1030016

Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho

Sponsors

Collaborators (1)

Chugai Pharmaceutical
All Listed Sponsors
collaborator

Chugai Pharmaceutical

INDUSTRY

lead

Japan Breast Cancer Research Group

OTHER

NCT01989780 - Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | Biotech Hunter | Biotech Hunter